(MCRC Non-Clinical) Metabolic Drivers of Leukaemia Pathogenesis and Therapy Resistance
The University of Manchester
Division of Cancer Sciences
Chronic myelomonocytic leukaemia (CMML) is an aggressive myeloid blood cancer defined by expansion of malignant monocytes. Hypomethylating agents (HMAs), such as azacitidine and decitabine, are the only standard-of-care disease-modifying therapies, but 50–70% of patients fail to respond. Read more
Supervisors: Dr K Batta, Dr D Wiseman, Dr D K Trivedi, Dr CR Rivera Rivera
23 November 2026
PhD Research Project
Competition Funded PhD Project (Students Worldwide)